[hν]: 11% dr > 20:1 synthesize these compounds are much longer, involving numerous reactions that are undesired from both safety (toxic intermediates, hazardous/explosive reagents, high-pressure reaction) and sustainability (precious metal-based hydrogenation) perspectives. In some cases, the enantioselective step requires Ru-based catalysts (Noyori reduction for 27) or complex thiourea catalysts (asymmetric Henry reaction for 1). The Ni-electrocatalytic approach can now offer new access to an emerging tuberculosis medicine, GSK-656 (4). Thus, unique boron-containing drug candidate exhibits highly selective inhibitory activity to Mycobacterium tuberculosis leucyl-tRNA synthetase (LeuRS) and is currently in Phase II clinical trials as a promising candidate for multidrug-resistant tuberculosis. The current most practical synthesis involves a 9-step route using an asymmetric Cu-catalyzed Henry reaction as a key step for the construction of the aminoalcohol motif. Although the route is optimized and scalable, multiple Pd-based hydrogenation steps and redox manipulations reduce ideality. In contrast, the Ni-electrocatalytic approach enables straightforward access to 4 by simply coupling the aminoalcohol unit into aryl iodide 12, followed by boron-installation and protecting group removal. Notably, overall yield was considerably improved (33% compared to 7% in the previous route). This particular coupling (12+11) was easily performed on gram-scale without the Ag additive, albeit in slightly diminished yield, demonstrating robustness of the electrochemical coupling. Finally, the Ni-electrocatalytic